公开(公告)号：EP2364992A1

公开(公告)日：2011-09-14

申请号：EP11162832.7

申请日：2007-06-12

Applicant: Cell Therapeutics, Inc. - Sede Secondaria ,  CELL THERAPEUTICS, INC.

Inventor： McKennon, Marc ,  Da Re, Giovanni ,  Feliciotti, Luca ,  Artico, Marco ,  Pardi, Gianluca ,  Grugni, Mario

IPC: C07K14/00 ,  C08G69/10 ,  C07K1/00 ,  A61K47/48

CPC classification number: C07K1/02 ,  C07K14/001 ,  C08G69/10

Abstract: The invention relates to an improved process for the preparation of poly-α-glutamic acids which comprises the polymerisation of tertiary γ-esters of α-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-α-glutamic acid-γ-ester. The process is particularly advantageous in that it allows to carefully control the molecular weight of the resulting poly-α-glutamic acid. The invention also relates to poly-α-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof.

Abstract translation: 本发明涉及一种制备聚-γ-谷氨酸的改进方法，其包括用合适的溶剂和引发剂将± - 谷氨酸N-羧酸酐的叔-3-酯聚合，然后酸化所得聚 - ± - 谷氨酸-3-酯。 该方法特别有利的是，其允许仔细控制得到的聚-γ-谷氨酸的分子量。 本发明还涉及在氨基末端用羧酸或氨基酸封端的聚-γ-谷氨酸及其制备方法。

公开(公告)号：US20040162288A1

公开(公告)日：2004-08-19

申请号：US10712900

申请日：2003-11-13

Applicant: Cell Therapeutics, Inc.

Inventor： Baoqing Gong ,  John Tulinsky ,  Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20040082049A1

公开(公告)日：2004-04-29

申请号：US10667462

申请日：2003-09-23

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Daniel Adourel ,  David Hollenback

IPC: C12N009/10

CPC classification number: C12N9/1029

Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

公开(公告)号：US20030216414A1

公开(公告)日：2003-11-20

申请号：US10434097

申请日：2003-05-09

Applicant: Cell Therapeutics,Inc.

Inventor： Stuart L. Bursten ,  Jack W. Singer ,  Glenn C. Rice

IPC: A61K031/55 ,  A61K031/53 ,  A61K031/519 ,  A61K031/522 ,  A61K031/517

CPC classification number: A61K31/00 ,  A61K31/52

Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

公开(公告)号：US20030153570A1

公开(公告)日：2003-08-14

申请号：US10285364

申请日：2002-10-30

Applicant: Cell Therapeutics, Inc.

Inventor： Rama Bhatt ,  Baoqing Gong ,  Feng Hong ,  Scott A. Jenkins ,  J. Peter Klein ,  Anil M. Kumar ,  John Tulinsky

IPC: A61K031/53 ,  C07D251/48 ,  C07D43/02

CPC classification number: C07D403/12 ,  C07D251/16 ,  C07D251/18 ,  C07D251/22 ,  C07D405/12

Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity and/or proliferation of cells such as tumor cells.

Abstract translation: 本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

公开(公告)号：US20020103211A1

公开(公告)日：2002-08-01

申请号：US09725016

申请日：2000-11-29

Applicant: Cell Therapeutics, Inc.

Inventor： Baoqing Gong ,  J. Peter Klein ,  Michael Coon

IPC: A61K031/522 ,  A61K031/675

CPC classification number: C07D487/14 ,  A61K31/522 ,  A61K31/675 ,  C07D513/14

Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

Abstract translation: 发现新的三环化合物可用于治疗或预防与受细胞因子细胞内信号传导影响的疾病或病症相关的症状或表现。

公开(公告)号：US20020103195A1

公开(公告)日：2002-08-01

申请号：US09984888

申请日：2001-10-31

Applicant: CELL THERAPEUTICS,INC.

Inventor： Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53 ,  C07D413/14 ,  C07D43/14

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20230086868A1

公开(公告)日：2023-03-23

申请号：US18058425

申请日：2022-11-23

Applicant: Lineage Cell Therapeutics, Inc. ,  Hadasit Medical Research Services and Development Ltd.

Inventor： Francois Binette ,  Gary Hogge ,  Rami Skaliter ,  Avi Ben Shabat ,  Jordi Monés ,  Eyal Banin ,  Tina Guanting Qiu

IPC: A61K35/30 ,  A61K9/00 ,  A61P27/02 ,  A61P9/10

Abstract: Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.

公开(公告)号：US20220354896A1

公开(公告)日：2022-11-10

申请号：US17606990

申请日：2020-04-28

Applicant: LINEAGE CELL THERAPEUTICS, INC.

Inventor： Igor NASONKIN ,  Ratnesh SINGH ,  Francois BINETTE

IPC: A61K35/30 ,  C12N5/079 ,  A61P27/02 ,  A61K9/00

Abstract: Presented herein are compositions and methods for generating stem cell derived retinal tissue and isolated retinal progenitor cells for use in the treatment of retinal degenerative diseases and disorders.

公开(公告)号：US20220267723A1

公开(公告)日：2022-08-25

申请号：US17277548

申请日：2019-09-19

Applicant: Lineage Cell Therapeutics, Inc.

Inventor： Rekha R. Nair ,  Stephanie Kayser ,  Abhirath S. PARIKH ,  Uzma Shoukat-Mumtaz ,  Erik Michael Whiteley ,  Nathan C. Manley ,  Craig R. Halberstadt

IPC: C12N5/079

Abstract: Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided. Also provided are methot and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.